Prophylactic oophorectomy and hormone replacement therapy: Protection at what price?

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 978-980

  Garber, Judy Ellen ^a   Hartman, Anne Renee ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; PROGESTERONE;

BREAST CANCER; CANCER RISK; COST BENEFIT ANALYSIS; EDITORIAL; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; DECISION SUPPORT SYSTEM; ESTROGEN THERAPY; FEMALE; GENETIC PREDISPOSITION; GENETICS; NOTE; OVARY TUMOR; PROBABILITY; TUMOR SUPPRESSOR GENE;

DECISION SUPPORT TECHNIQUES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MARKOV CHAINS; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 1842509907     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.926     Document Type: Editorial

References (16)

1. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study-A randomized controlled trial. JAMA 289:2651-2662, 2003
2. Rapp SR, Espeland MA, Shumaker SA, et al: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study - A randomized controlled trial. JAMA 289:2663-2672, 2003
3. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289:3243-3253, 2003
4. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al: Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative - A randomized trial. JAMA 289:2673-2684, 2003
5. 4a. Armstrong K, Sanford Schwartz J, Randall T, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 22:1045-1054, 2004
6. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
7. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
8. Sellers TA, Grabrick DM, Hartmann LC: Oral contraceptives and risk of breast cancer in women with a family history of breast cancer. JAMA 285:39-40, 2001
9. Ursin G, Henderson BE, Haile RW, et al: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?. Cancer Res 57:3678-3681, 1997
10. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
11. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
12. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
13. Warner E, Plewes DB, Shumak RS, et al: Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524-3531, 2001
14. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al: First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 63:53-60, 2000
15. Kuhl CK, Schmutzler RK, Leutner CC, et al: Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 215:267-279, 2000
16. Peshkin BN, Isaacs C, Finch C, et al: Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: A pilot survey of physicians. J Clin Oncol 21:4322-4328, 2003